Ecological Validity of the Montreal Cognitive Assessment in Non-Demented Parkinson's Disease Patients.

Cognitive screening Ecological validity Montreal Cognitive Assessment Parkinson’s disease Psychometrics

Journal

Neuro-degenerative diseases
ISSN: 1660-2862
Titre abrégé: Neurodegener Dis
Pays: Switzerland
ID NLM: 101189034

Informations de publication

Date de publication:
2022
Historique:
received: 24 04 2023
accepted: 06 07 2023
pubmed: 24 7 2023
medline: 24 7 2023
entrez: 23 7 2023
Statut: ppublish

Résumé

The ecological validity of performance-based cognitive screeners needs to be tested in order for them to be fully recommended for use within clinical practice and research. The objective of this study was to examine, within an Italian cohort of non-demented Parkinson's disease (PD) patients, the ecological validity of the Montreal Cognitive Assessment (MoCA) by assessing its association with (1) functional independence (FI), (2) quality of life (QoL), and (3) behavioural-psychological (BP) outcomes. Seventy-four non-demented PD patients were administered the MoCA and underwent motor functional - i.e., Unified Parkinson's Disease Rating Scale (UPDRS), Modified Hoehn-Yahr Scale (HY), and Schwab and England Scale (SES) -, behavioural and psychological - i.e., State- and Trait-Anxiety Inventory-Form Y (STAI-Y1/-Y2), Beck Depression Inventory (BDI), and Dimensional Apathy Scale (DAS) - and QoL evaluations - i.e., MOS 36-Item Short Form Health Survey (SF-36). Associations of interest against FI, QoL, and BP outcomes were tested via Bonferroni-corrected Pearson's/Spearman's correlations while covarying for demographics, disease duration as well as UPDRS-III, UPDRS-IV, and HY scores. Intake of psychotropic drugs was also covaried when assessing the association between the MoCA and BP/QoL measures. MoCA scores were significantly associated with the SES (rs(73) = 0.34; p = 0.005) and the DAS-Executive (r(67) = -0.47; p < 0.001), while not to other FI/BP outcomes and QoL measures. The MoCA is a valid estimate of daily life functional autonomy in non-demented PD patients, also reflecting apathetic features of a dysexecutive nature.

Sections du résumé

BACKGROUND BACKGROUND
The ecological validity of performance-based cognitive screeners needs to be tested in order for them to be fully recommended for use within clinical practice and research.
OBJECTIVES OBJECTIVE
The objective of this study was to examine, within an Italian cohort of non-demented Parkinson's disease (PD) patients, the ecological validity of the Montreal Cognitive Assessment (MoCA) by assessing its association with (1) functional independence (FI), (2) quality of life (QoL), and (3) behavioural-psychological (BP) outcomes.
METHODS METHODS
Seventy-four non-demented PD patients were administered the MoCA and underwent motor functional - i.e., Unified Parkinson's Disease Rating Scale (UPDRS), Modified Hoehn-Yahr Scale (HY), and Schwab and England Scale (SES) -, behavioural and psychological - i.e., State- and Trait-Anxiety Inventory-Form Y (STAI-Y1/-Y2), Beck Depression Inventory (BDI), and Dimensional Apathy Scale (DAS) - and QoL evaluations - i.e., MOS 36-Item Short Form Health Survey (SF-36). Associations of interest against FI, QoL, and BP outcomes were tested via Bonferroni-corrected Pearson's/Spearman's correlations while covarying for demographics, disease duration as well as UPDRS-III, UPDRS-IV, and HY scores. Intake of psychotropic drugs was also covaried when assessing the association between the MoCA and BP/QoL measures.
RESULTS RESULTS
MoCA scores were significantly associated with the SES (rs(73) = 0.34; p = 0.005) and the DAS-Executive (r(67) = -0.47; p < 0.001), while not to other FI/BP outcomes and QoL measures.
CONCLUSIONS CONCLUSIONS
The MoCA is a valid estimate of daily life functional autonomy in non-demented PD patients, also reflecting apathetic features of a dysexecutive nature.

Identifiants

pubmed: 37482058
pii: 000532115
doi: 10.1159/000532115
doi:

Types de publication

News

Langues

eng

Sous-ensembles de citation

IM

Pagination

159-163

Informations de copyright

© 2023 S. Karger AG, Basel.

Auteurs

Edoardo Nicolò Aiello (EN)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy, e.aiello5@campus.unimib.it.

Alfonsina D'Iorio (A)

Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy.

Federica Solca (F)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.

Silvia Torre (S)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.

Eleonora Colombo (E)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.

Alessio Maranzano (A)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.

Alberto De Lorenzo (A)

Neurology Residency Program, Università degli Studi di Milano, Milano, Italy.

Valerio Patisso (V)

Neurology Residency Program, Università degli Studi di Milano, Milano, Italy.

Mauro Treddenti (M)

Neurology Residency Program, Università degli Studi di Milano, Milano, Italy.

Claudia Morelli (C)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.

Alberto Doretti (A)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.

Luca Maderna (L)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.

Federico Verde (F)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.
Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Università degli Studi di Milano, Milano, Italy.

Roberta Ferrucci (R)

Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.
ASST Santi Paolo e Carlo, San Paolo University Hospital, Milano, Italy.

Sergio Barbieri (S)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

Fabiana Ruggiero (F)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

Alberto Priori (A)

ASST Santi Paolo e Carlo, San Paolo University Hospital, Milano, Italy.
"Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Milano, Italy.

Vincenzo Silani (V)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.
Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Università degli Studi di Milano, Milano, Italy.

Nicola Ticozzi (N)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.
Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Università degli Studi di Milano, Milano, Italy.

Gabriella Santangelo (G)

Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy.

Andrea Ciammola (A)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.

Barbara Poletti (B)

Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.

Classifications MeSH